Loading...
Scancell Holdings plc
SCNLF•PNK
Healthcare
Biotechnology
$0.14
$0.00(0.00%)

Over the last four quarters, Scancell Holdings plc achieved steady financial progress, growing revenue from $2.64M in Q1 2023 to $5.27M in Q4 2023. Gross profit stayed firm with margins at 82% in Q4 2023 versus 90% in Q1 2023. Operating income totaled -$4.67M in Q4 2023, maintaining a -89% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$4.23M. Net income dropped to -$8.77M, with EPS at -$0.01. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan